Home∕News & Press∕Featured∕Neil Singla, MD, Chief scientific Officer of Lotus Clinical Research to chair the American Pain Society’s 2nd annual Conference on Analgesic Trials 36th Annual Scientific Meeting May. 17, 2017 Neil Singla, MD, Chief scientific Officer of Lotus Clinical Research, will chair the American Pain Society’s 2nd annual Conference on Analgesic Trials (APS-CAT) on May 17, 2017 in Pittsburgh, Pennsylvania, as a part of APS’ 36th Annual Scientific Meeting. The full-day session will discuss methods to optimize the complex process of analgesic drug development. We had over 200 pain researchers in attendance at the first event in 2016, discussing the design and conduct of analgesic clinical trials with an 8-member expert panel. Audience feedback was overwhelmingly positive. APS’ second annual APS-CAT will be held on May 17, 2017 (day 1 of APS’ Annual Scientific Meeting) at the David L. Lawrence Convention Center in Pittsburgh, PA. Link to register: https://apps.americanpainsociety.org/Default.aspx?TabId=229&ProductId=12878315 (Navigate to “May 17” tab and select “(002) APS Conference on Analgesic Trials”). Registration is $100, and includes lunch and refreshments. APS-CAT 2017 confirmed presenters include: Sharon Hertz, MD – Director, FDA Division of Anesthesia, Analgesia, and Addiction Products Bob Rappaport, MD – Founder, Analgesic Concepts, Former Director, FDA Division of Anesthesia, Analgesia, and Addiction Products, Getting the Indication You Want: Selecting An Appropriate Analgesic Model Neil Singla, MD – Chief Scientific Officer, Lotus Clinical Research, Opioid Sparing Endpoints: Trial Design, Clinical Relevance and Label Claims Lars Arendt-Nielsen, Dr. Med., PhD – Center for Sensory-Motor Interaction (SMI), Department of Health Science and Technology, School of Medicine, Aalborg University, Translational, Quantitative, Healthy Volunteer Pain Models of Pain and Sensitization Nathaniel Katz, MD – President, Analgesic Solutions, What Can Be Done About the Placebo Response in Clinical Trials: A Review of the Evidence Laurie Burke, MD – Founder, LORA Group, Former Director, FDA Study Endpoints and Labeling Development (SEALD) Team, Getting the Claims You Want: Optimizing Your Study Endpoints and Labeling Lee Simon, MD – Principal, SDG, LLC, Former Director, FDA Division of Analgesic, Anti-inflammatory and Ophthalmologic Drug Products, Clinical Trial Design Considerations for Studies in Osteoarthritis Roy Freeman, MD – Professor of Neurology, Harvard Medical School, Director, Center for Autonomic and Peripheral Nerve Disorders, Beth Israel Deaconess Medical Center, Clinical Trial Design Considerations for Studies in Diabetic Peripheral Neuropathy APS-CAT is a full-day conference focused on optimizing the design and conduct of analgesic clinical trials. APS-CAT involves audience members in dialogue with thought leaders in the field to disseminate the latest scientific and regulatory developments and facilitate collaboration. The conference features a panel format, with each presenter speaking for 30 minutes followed by Q & A. Our goal is to maximize the efficiency of analgesic drug development. You don’t have to sign up for the full APS meeting to attend APS-CAT, but APS offers 3 additional days of scientific content. CRO SERVICES SITE SERVICES PLACEBO RESPONSE MITIGATION ANALGESIC EXPERTISE RESOURCE WHO WE ARE Participate in Trial Contact Us Terms of Use Privacy Policy © 2021 Lotus Clinical Research, LLC. All Rights Reserved.